Erlotinib gel - Sol-Gel Technologies
Alternative Names: SGT 210Latest Information Update: 28 May 2025
At a glance
- Originator Sol-Gel Technologies
- Class Alkynes; Antineoplastics; Quinazolines; Skin disorder therapies; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Skin disorders
- Preclinical Pachyonychia congenita
- No development reported Actinic keratosis; Palmoplantar keratoderma; Skin cancer
Most Recent Events
- 28 May 2025 No recent reports of development identified for phase-I development in Palmoplantar keratoderma in Israel (Topical, Gel)
- 28 May 2025 No recent reports of development identified for preclinical development in Actinic keratosis in Israel (Topical)
- 28 May 2025 No recent reports of development identified for preclinical development in Skin-cancer in Israel (Topical, Gel)